Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
97 participants
INTERVENTIONAL
2017-12-01
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The current drug regimen for treating tuberculosis is lengthy and onerous, and hence complicated by poor compliance leading to drug resistance and disease relapse. Previously, using an output-driven optimization platform, parabolic response surface (PRS, previously called Feedback System control or FSC), and an in vitro macrophage model of Mycobacterium tuberculosis infection, we identified several new experimental drug regimens among billions of possible drug-dose combinations that outperform the current Standard Regimen. We used the PRS platform to optimize the in vivo drug doses of novel regimens (designated PRS regimen) in a mouse model of pulmonary tuberculosis and then showed that the regimens sterilized much more rapidly than the Standard Regimen and substantially reduced treatment time to relapse-free cure by 25% for PRS regimen, which consists of Clofazimine (Cfz), Ethambutol (E), high dose Pyrazinamide (Z, high), and Prothionamide (Pto). The regimen have the potential to provide a markedly shorter course of treatment for tuberculosis in humans. As PRS regimen omit isoniazid, rifampicin, fluoroquinolones, and injectable aminoglycosides, they are suitable for treating many cases of multidrug and extensively drug-resistant tuberculosis.
1 Significance of the study Based on results in cell culture in macrophages and in mice we anticipate that PRS regimen will prove to be more effective and will allow a shorter course of treatment than the standard regimen. By allowing a shorter course of treatment, problems with adherence, toxicity, and development of drug resistance can be reduced. Moreover, because the regimen does not include INH or RIF, it can be used in cases of TB that are resistant to those drugs.
2 Methods
1. Summary of Experimental Design This is a randomized, controlled, open-label pilot clinical trial. Previously untreated, smear positive tuberculosis patients (aged 18 - 65 years) with radiographic evidence of TB and whose bacteria are sensitive to first-line drugs will be randomly distributed to group A (standard regimen) and B (new short course PRS regimen). The study will compare sputum conversion rate at the end of treatment between treatment regimens and will evaluate objective indicators of treatment success rate and incidence of adverse events.
2. Identification of Subjects: Potentially eligible subjects will be identified from among subjects seen at or referred to the Shanghai Pulmonary Hospital for treatment of tuberculosis. Subjects will be informed about the study and those who express interest in participation will be provided a written consent form.
3. Consent Process: As described in detail below, Subjects will be informed that participation is voluntary and that they will receive appropriate care for their condition regardless of whether or not they participate in the study. Because subjects have active TB, they will be in isolation in the Shanghai Pulmonary Hospital. The investigator will review the consent form with the subject and ensure that the subject understands the consent form and that all of the subject's questions have been answered. Because timely initiation of treatment is important, subjects will be allowed up to two days to decide whether to participate in the study or to receive standard care.
4. Screening for Eligibility: Screening tests indicated in the Table of Study Procedures (located at the end of this document) and required for assessment of eligibility per inclusion/exclusion criteria will be completed within 14 days prior to study enrollment.
5. Randomization: Eligible subjects will be randomized 1:1 by using a random number generator either to Group A (standard care) or to Group B (the investigational PRS regimen).
6. Study Treatment: Subjects are treated according to their assignment to Group A or Group B as indicated below.
Group A, Standard Regimen (2EHRZ/4HR): The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
All drugs are administered orally, seven days/week. Study drugs are dosed by weight as shown in the below. Group B, PRS Regimen (4EZ \[high dose\] Cfz Pto): The PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight according to below.
The drug dosing for both Group A and Group B are summarized in the below:
………………………………………………………………………………………………………………………… Isoniazid (H):daily dose (gm)0.3(weight \<50kg);0.3(weight≥50kg),use method: 1 times/day.
Rifampin (R):daily dose (gm)0.45(weight \<50kg);0.6(weight≥50kg),use method: 1 times/day（Fasting medication）.
ethambutol (E):daily dose (gm)0.75(weight \<50kg);1.0(weight≥50kg),use method: 1～2 times/day.
pyrazinamide (Z):daily dose (gm)1.5(weight \<50kg);1.5(weight≥50kg),use method:1～3 times/day.
Pyrazinamide (High dose):daily dose (gm)1.75(weight \<50kg);2.0(weight≥50kg),use method:1～2 times/day.
clofazimine（Cfz）:daily dose (gm)0.15(weight \<50kg);0.15(weight≥50kg),use method:1～3times/day.
prothionamide（Pto）:daily dose (gm)0.6(weight \<50kg);0.6(weight≥50kg),use method: 3 times/day.
……………………………………………………………………………………………………………
7. Patient follow up After 6-months standard treatment or 4-months short term PRS regimen treatment, subjects will have long term follow up to evaluate efficacy and ensure absence of relapse. The checkup times are at 1 month, 3 months, 6 months, 12 months and 24 months.
Evaluation of Efficacy i Bacteriology: sputum smear microscopy, culture using the Becton Dickinson Company mycobacterial growth indicator tube (MGIT) system and Lowenstein-Jensen (LJ) slant culture. MGIT testing will be used to evaluate drug susceptibility .
ii Radiology: All patients undergo chest X-ray and CT scan before treatment. X-ray will be reviewed after 8 weeks of treatment and at end of treatment and during the follow-up period. CT scan will be reviewed at end of treatment.
iii Bacterial load of sputum samples will be evaluated within two weeks after the start of treatment.
iv Time to culture positivity: Time to culture positivity will be performed by MGIT culture within two months after the start of treatment.
v Evaluation of results: We shall employ the World Health Organization (WHO) uniform standards in evaluating cure rate and treatment success rate, the sputum negative conversion rate, incidence of adverse events and patient compliance and other indicators. We shall compare these outcomes between the experimental group and the standard group to analyze the effect of each treatment regime.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A (the standard 2HRZE/4HR regimen)
Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
Group A (the standard 2HRZE/4HR regimen）
The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
Group B, PRS Regimen (4EZ \[high dose\] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group A (the standard 2HRZE/4HR regimen）
The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Pulmonary lesion consistent with TB by radiological examination
3. Positive sputum culture, identification of bacterial type confirmed Mycobacterium tuberculosis. MGIT drug sensitivity test (DST) results are sensitive of the first-line drugs (isoniazid, streptomycin, rifampicin and ethambutol).
4. Age 18 years-65 years old
5. Males or non-pregnant, non-nursing females
6. Women of child-bearing potential who are not surgically sterilized must agree to practice a barrier method of contraception or abstain from heterosexual intercourse during study drug treatment.
a.Effective birth control methods: i.A double contraceptive method should be used as follows: ii.Double barrier method which can include any 2 of the following: a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together); or iii.Barrier method (one of the above) combined with hormone-based contraceptives or an intra-uterine device for the female subject/partner; iv.and are willing to continue practicing birth control methods throughout treatment and for 6 months (both male and female subjects) after the last dose of study medication or discontinuation from study medication in case of premature discontinuation.
7. Laboratory parameters done at or within 14 days prior to screening:
1. Serum or plasma aminotransferases (AST, ALT) less than 3 times the upper limit of normal
2. Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit of normal
3. Serum or plasma creatinine level less than or equal to 2 times the upper limit of normal
4. Serum or plasma potassium level greater than or equal to 3.5 meq/L
5. Hemoglobin level of 7.0 g/dL or greater
6. Platelet count of 100,000/mm3 or greater
7. For women of childbearing potential, a negative pregnancy test is required during screening
8. Provides written informed consent
9. Willingness and ability to attend scheduled follow-up visits and undergo study assessments.
Exclusion Criteria
2. Unable to take oral medications.
3. History of allergy or intolerance to any of the study drugs
4. Serum aminotransferase (AST or ALT) 3x upper limit of normal or higher
5. Pregnant or nursing females, or plan to become pregnant or nurse during the study period
6. Males planning to conceive a child during the study or within 6 months of cessation of treatment.
7. Any treatment directed against active tuberculosis within 6 months preceding initiation of study drugs.
8. Suspected or documented tuberculosis involving the central nervous system and/or bones and/or joints, and/or miliary tuberculosis and/or pericardial tuberculosis.
9. HIV infected
10. HBV infected or HCV infected (these increase the risk of TB-drug induced hepatotoxicity)
11. Weight less than 40.0 kg.
12. Known allergy or intolerance to any of the study medications.
13. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any of the study drugs.
14. QTcF \> 500 msec
15. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest.
16. Current or planned incarceration or other involuntary detention
17. Having participated in other clinical studies with dosing of investigational agents within 8 weeks prior to trial start or currently enrolled in an investigational study that includes treatment with medicinal agents. Subjects who are participating in observational studies or who are in a follow up period of a trial that included drug therapy may be considered for inclusion.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Center for Disease Control and Prevention
OTHER
No.85 Hospital, Changning, Shanghai, China
OTHER
Shanghai Public Health Clinical Center
OTHER_GOV
Bill and Melinda Gates Foundation
OTHER
University of California, Los Angeles
OTHER
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Sha MD & PhD
Director, Head of Tuberculosis Department,Shanghai Pulmonary Hospital, Principal Investigator, Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
sha wei
Role: PRINCIPAL_INVESTIGATOR
Shanghai Pulmonary Hospital, Shanghai, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eighty-fifth Hospital of PLA
Shanghai, , China
Shanghai Public Health Clinical Center Shanghai, China
Shanghai, , China
Shanghai Center for Disease Control and Prevention
Shanghai, , China
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013 May;12(5):388-404. doi: 10.1038/nrd4001.
Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB. Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015 Mar;3(3):220-34. doi: 10.1016/S2213-2600(15)00063-6. Epub 2015 Mar 9.
Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology. 2010 Jul;15(5):764-78. doi: 10.1111/j.1440-1843.2010.01775.x. Epub 2010 Jun 4.
Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9. Epub 2010 May 18.
Silva A, Lee BY, Clemens DL, Kee T, Ding X, Ho CM, Horwitz MA. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2172-9. doi: 10.1073/pnas.1600812113. Epub 2016 Mar 28.
Lee BY, Clemens DL, Silva A, Dillon BJ, Maslesa-Galic S, Nava S, Ding X, Ho CM, Horwitz MA. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time. Nat Commun. 2017 Jan 24;8:14183. doi: 10.1038/ncomms14183.
Handbook of anti-tuberculosis agents. Introduction. Tuberculosis (Edinb). 2008 Mar;88(2):85-6. doi: 10.1016/S1472-9792(08)70002-7. No abstract available.
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. doi: 10.1164/rccm.200510-1666ST.
Related Links
Access external resources that provide additional context or updates about the study.
WHO. 2015. Global Tuberculosis Report 2015.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
K18-103
Identifier Type: -
Identifier Source: org_study_id